Clinical Pharmacokinetics and Pharmacometrics Group, Clinical Pharmacology, Clinical Research Division, Japan Development, MSD K.K., Tokyo, Japan.
Faculty of Medicine, Graduate School of Medicine, Oita University, Oita, Japan.
Clin Pharmacol Ther. 2019 Apr;105(4):1018-1030. doi: 10.1002/cpt.1240. Epub 2018 Dec 4.
Pharmacokinetics (PKs) in Japanese healthy subjects were simulated for nine compounds using physiologically based PK (PBPK) models parameterized with physicochemical properties, preclinical absorption, distribution, metabolism, and excretion (ADME) data, and clinical PK data from non-Japanese subjects. For each dosing regimen, 100 virtual trials were simulated and predicted/observed ratios for peak plasma concentration (C ) and area under the curve (AUC) were calculated. As qualification criteria, it was prespecified that >80% of simulated trials should demonstrate ratios to observed data ranging from 0.5-2.0. Across all compounds and dose regimens studied, 93% of simulated C values in Japanese subjects fulfilled the criteria. Similarly, for AUC, 77% of single-dosing regimens and 100% of multiple-dosing regimens fulfilled the criteria. In summary, mechanistically incorporating the appropriate ADME properties into PBPK models, followed by qualification using non-Japanese clinical data, can predict PKs in the Japanese population and lead to efficient trial design and conduct of Japanese phase I studies.
在日本健康受试者中,使用基于生理学的药代动力学 (PBPK) 模型模拟了 9 种化合物的药代动力学 (PKs),这些模型参数化了物理化学性质、临床前吸收、分布、代谢和排泄 (ADME) 数据以及非日本受试者的临床 PK 数据。对于每种给药方案,模拟了 100 次虚拟试验,并计算了峰血浆浓度 (C ) 和曲线下面积 (AUC) 的预测/观察比值。作为资格标准,规定 >80%的模拟试验应显示比值在 0.5-2.0 之间。在所研究的所有化合物和剂量方案中,93%的日本受试者的模拟 C 值符合标准。同样,对于 AUC,单剂量方案的 77%和多剂量方案的 100%符合标准。总之,通过将适当的 ADME 特性纳入 PBPK 模型,并使用非日本临床数据进行资格验证,可以预测日本人群的 PK,并有助于高效的试验设计和日本 I 期研究的开展。